(Q64012993)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Model-based drug development: a rational approach to efficiently accelerate drug development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

P A Milligan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

M J Brown

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

B Marchant

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

S W Martin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

P H van der Graaf

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

N Benson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

G Nucci

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

D J Nichols

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

R A Boyd

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

J W Mandema

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

S Krishnaswami

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

S Zwillich

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

D Gruben

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

R J Anziano

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

T C Stock

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

R L Lalonde

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

14 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

502-514

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588322%20AND%20SRC:MED&resulttype=core&format=json

Model-based drug development

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

CPT: Pharmacometrics and Systems Pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Learning versus confirming in clinical drug development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Prevalence and genesis of endometriosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

A mathematical model of the human menstrual cycle for the administration of GnRH analogues.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH).

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Has the time come for predictive computer modeling in CNS drug discovery and development?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

A mechanistic, model-based approach to safety assessment in clinical development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Can animal models of disease reliably inform human studies?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Comparative efficacy and effectiveness: an opportunity for clinical pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021

Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.54

7 January 2021